Erste Group analyst Hans Engel downgraded Amgen (AMGN) to Hold from Buy. The company’s planned weight loss products are still in the clinical trial phase and are only likely to make moderate contributions to sales growth in the coming years, the analyst tells investors in a research note.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on AMGN:
- Amgen says MHRA granted marketing authorization to Tepezza for TED
- Amgen price target raised to $280 from $235 at Mizuho
- Amgen’s Mixed Financial Outlook: Strong Q1 Performance but Cautious Future Guidance Leads to Hold Rating
- Amgen’s Strong Financial Performance and Strategic Positioning Earns Buy Rating from Analyst
- Amgen Inc. Reports Strong Growth Amid Challenges
Looking for a trading platform? Check out TipRanks' Best Online Brokers guide, and find the ideal broker for your trades.
Report an Issue